De novo production of 24-epi-ergosterol in bioengineered yeast  

作　　者：XU Zi Fei DONG Liao-Bin 

机构地区：[1]State Key Laboratory of Natural Medicines,School of Traditional Chinese Pharmacy,China Pharmaceutical University,Nanjing 211198,China

出　　处：《Chinese Journal of Natural Medicines》2023年第5期321-322,共2页中国天然药物（英文版）

摘　　要：Plant natural products(PNPs),a rich source of structurally unique and functionally diverse bioactive compounds,comprise a large variety of natural product families including alkaloids,terpenoids,and phenylpropanoids[1].PNPs possess a wide range of applications such as antibiotics,analgesics,and antiviral,antimalarial and antineoplastic agents[2,3].Classically,collection of PNPs relies on extraction and purification from natural producers.However,due to their low amounts in nature,the extraction process is often inefficient and costly.Chemical synthesis,on the other hand,is difficult due to the stereochemical complexity of PNPs.In recent years,advances in synthetic biology have accelerated the process of producing complex PNPs in yeast cell factories.Saccharomyces cerevisiae(yeast)is charaterized by a wealth of well-established tools available for genetic manipulation,a well-characterized core metabolic network,low cultivation cost,and compatibility with high cell density fermentation[4-7].As a result,S.cerevisiae is increasingly used as a workhorse for enzyme characterization,biosynthetic pathway elucidation[8,9],and de novo production for various highvalue PNPs[10].

关 键 词：HORSE compatibility CULTIVATION 

分 类 号：R284[医药卫生—中药学]